Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comprehensive geriatric assessment is an independent prognostic factor in older patients with metastatic renal cell cancer treated with first-line Sunitinib or Pazopanib: a single center experience.
Pierantoni F, Basso U, Maruzzo M, Lamberti E, Bimbatti D, Tierno G, Bergo E, Brunello A, Zagonel V. Pierantoni F, et al. Among authors: bimbatti d. J Geriatr Oncol. 2021 Mar;12(2):290-297. doi: 10.1016/j.jgo.2020.09.009. Epub 2020 Sep 21. J Geriatr Oncol. 2021. PMID: 32972885
Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma.
Bimbatti D, Ciccarese C, Fantinel E, Sava T, Massari F, Bisogno I, Romano M, Porcaro A, Brunelli M, Martignoni G, Mazzarotto R, Artibani W, Tortora G, Iacovelli R. Bimbatti D, et al. Urol Oncol. 2018 Dec;36(12):526.e13-526.e18. doi: 10.1016/j.urolonc.2018.08.018. Epub 2018 Oct 6. Urol Oncol. 2018. PMID: 30301699
Second-line therapy for metastatic urothelial carcinoma: Defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis.
Ciccarese C, Iacovelli R, Bria E, Mosillo C, Bimbatti D, Fantinel E, Bisogno I, Brunelli M, Tortora G. Ciccarese C, et al. Among authors: bimbatti d. Semin Oncol. 2019 Feb;46(1):65-72. doi: 10.1053/j.seminoncol.2019.01.001. Epub 2019 Jan 14. Semin Oncol. 2019. PMID: 30665685
The prognostic value of pain in castration-sensitive prostate cancer.
Iacovelli R, Ciccarese C, Caffo O, De Giorgi U, Tucci M, Mosillo C, Bimbatti D, Pierantoni F, Maines F, Casadei C, Buttigliero C, Milella M, Tortora G. Iacovelli R, et al. Among authors: bimbatti d. Prostate Cancer Prostatic Dis. 2020 Dec;23(4):654-660. doi: 10.1038/s41391-020-0255-x. Epub 2020 Jul 10. Prostate Cancer Prostatic Dis. 2020. PMID: 32651468
Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7).
Santini D, Stellato M, De Giorgi U, Pantano F, De Lisi D, Casadei C, Maruzzo M, Bimbatti D, Naglieri E, Buti S, Bersanelli M, De Vivo R, Di Lorenzo G, Sbrana A, Verzoni E, Soraru' M, Fornarini G, Mucciarini C, Grillone F, Mini E, Vignani F, Attademo L, Pignata S, Procopio G. Santini D, et al. Among authors: bimbatti d. Am J Clin Oncol. 2021 Mar 1;44(3):121-125. doi: 10.1097/COC.0000000000000791. Am J Clin Oncol. 2021. PMID: 33617179
Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators.
Stellato M, Procopio G, De Giorgi U, Maruzzo M, Bimbatti D, Mennitto A, Sbrana A, Roviello G, Casadei C, Sepe P, Pignata S, Santini D. Stellato M, et al. Among authors: bimbatti d. J Transl Med. 2021 Aug 3;19(1):328. doi: 10.1186/s12967-021-03008-9. J Transl Med. 2021. PMID: 34344414 Free PMC article.
70 results